Comprehensive Hematology Oncology LLC

1. Regeneron Pharmaceuticals, Inc. $68,485 21 payments
2. Institut de Recherches Internationales Servier $68,324 4 payments
3. Mirati Therapeutics, Inc. $34,421 3 payments
4. Octapharma USA, Inc. $28,800 5 payments
5. Sobi, Inc $19,967 16 payments
6. Ucb SA $13,554 12 payments
7. Sanofi US Services Inc. $13,240 9 payments
8. MorphoSys AG $12,198 3 payments
9. AbbVie, Inc. $9,369 4 payments

1. Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab VS Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (Sunlight) $68,324 4 payments
2. A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% $63,078 19 payments
3. A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy $34,421 3 payments
4. Ngam-12 $28,800 5 payments
5. Ava-Itp-401 $19,967 16 payments
6. A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent Or Chronic Primary Immune Thrombocytopenia (Itp) $13,554 12 payments
7. A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) $13,240 9 payments
8. realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients $12,198 3 payments
9. A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-Pd-1 Antibody) and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer $5,408 2 payments
10. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) $3,513 1 payment

1. Patient care $34,421 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.